HIV hyperimmune globulin or intravenous immune globulin inhibits response to an HIV vaccine

• Published in: Biotechnology and applied biochemistry 1998-04, Vol.27 (2), p.89-95
• Main Authors: Jelonek, Marie T., Maskrey, Jennifer L., Cummins, Larry M., Arora, Yogesh, Steimer, Kathelyn S., White‐Scharf, Mary, Keller, Margaret A.
• Format: Article
• Language: English
• Subjects: AIDS Vaccines - immunology; AIDS Vaccines - pharmacology; AIDS/HIV; Amino Acid Sequence; Analysis of the immune response. Humoral and cellular immunity; Animals; Antibody production; Biological and medical sciences; Disease Models, Animal; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; HIV Antibodies - pharmacology; HIV Envelope Protein gp120 - immunology; Humans; Immunity, Maternally-Acquired - drug effects; Immunobiology; Immunoglobulin G - analysis; Immunoglobulin G - drug effects; Immunoglobulins, Intravenous - pharmacology; Mice; Mice, Inbred BALB C; Molecular Sequence Data
• ISSN: 0885-4513; 1470-8744
• DOI: 10.1111/j.1470-8744.1998.tb01379.x

The murine model was developed to assess the effects of maternally transferred HIV hyperimmune globulin or human intravenous immune globulin on the immunization of the offspring at 18–21 days of age with rgp120SF2‐complete Freunds adjuvant. Either HIV hyperimmune globulin or intravenous immune globulin was administered intraperitoneally to post‐partum BALB/c mice and was transferred via milk to the offspring. Both HIV hyperimmune globulin and intravenous immune globulin inhibited the offspring anti‐rgp120SF2 IgG response to the vaccine. The HIV hyperimmune globulin inhibition persisted for 28 days after immunization while the intravenous immune globulin inhibition was still present at 63 days after immunization. In addition, the intravenous immune globulin had a more generalized immunosuppressive effect, inhibiting the IgG response to both rpg120SF2 and an additional protein antigen, hen egg‐white lysozyme. Effects of maternal or exogenously administered pre‐existing antibody, including control antibodies (intravenous immune globulin), on the newborn response to HIV and other vaccines must be carefully evaluated when vaccine studies proceed in newborns.